Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

20103,002 citationsJournal Articlebronze Open Access

Authors

Faı̈ez Zannad · Centre d’Investigation Clinique Innovation Technologique de Nancy

John J.V. McMurray

Henry Krum · Monash University

Dirk J. van Veldhuisen · University Medical Center Groningen

Karl Swedberg · University of Gothenburg

Harry Shi · Pfizer (United States)

John Vincent · Pfizer (United States)

Abstract

Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).

Topics & Keywords

Hormonal Regulation and Hypertension Adrenal Hormones and Disorders Electrolyte and hormonal disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 1, pp. 11-21

DOI: 10.1056/nejmoa1009492

Field-Weighted Citation Impact: 118.02